Seroloprevalence of Hepatits G Virus (HGV) in Beta-Thalassemia Patients Jahrom-Iran, 1399
نویسندگان
1 Dep of physiology, Jahrom university of medical science, Jahrom, Iran
2 School of medical Sciences, Sirjan, Iran
3 Dep of physiology, Jahrom university of medical science, Jahrom, Iran
4 Medical student, Tehran university of medical science, Tehran, Iran
5 Medical student, Shiraz university of medical science, Shiraz, Iran
6 Dep of physiology, Jahrom university of medical science, Jahrom, Iran
doi
10.22034/pjms.2022.700486چکیده
Introduction: People who have multiple transfusions, such as Beta-thalassemia patients, are at risk for the hepatitis Gvirus (HGV) infection. The aim of the study was the determination of serological prevalence of HGV and its associated factors in beta-thalassemia major patients in Jahrom-Iran.Materials and Methods: This cross-sectional study, was done on 91 beta-thalassemia patients referring to the thalassemia center, Jahrom-Iran, 2021. Blood samples were collected from the patients and anti-HGV antibodies were evaluated by ELISA methods. Serum levels of ALT, AST, ALP and demographic data were extracted from patients' medical records. Descriptive analysis, X2, and T-test were used for statistical analyses by SPSS-16.Results: The prevalence anti-HGV IgG and IgM were 18.7 % and 5.5 %, respectively. There were significant relationships between the frequencies of anti-HGV antibodies and serum level of ALT, ASL, ALP and also with the history time of transfusion (P<0.05). But, there were no significant relationships between the frequencies of anti-HGV antibodies with patients' sex and the mean of age (P>0.05).Conclusions: HGV is one of the etiologic factors of hepatitis in thalassemia patients in Jahrom. Further comprehensive and molecular-based studies are recommended to explore the prevalence of HGV and its role in hepatitis thalassemia patients.
